Iricryn

Bimatoprost, the active ingredient in Iricryn, is a prostaglandin analog presented as an ophthalmic solution for topical eye use. It lowers intra‑ocular pressure by increasing uveoscleral outflow, and is indicated for primary open‑angle glaucoma and ocular hypertension in adult patients. It is administered once daily in the affected eye(s) under medical supervision.

GNH USA supplies Iricryn as a licensed, GDP‑compliant international pharmaceutical supplier, meeting EU regulatory standards and providing the product to hospitals, pharmacies and clinics worldwide. The company adheres to Good Distribution Practice and ensures stable packaging for safe transport.

Bimatoprost is a prostaglandin analog used to manage ocular hypertension and glaucoma by reducing intra‑ocular pressure. - Primary open-angle glaucoma: reduces intra‑ocular pressure to help preserve visual field. - Ocular hypertension: lowers elevated eye pressure to prevent progression to glaucoma.

Bimatoprost eye drops may cause ocular and peri‑ocular adverse reactions, which are generally mild but can include more serious events.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Eyelash darkening: increased pigment of the lashes. - Dry eye sensation: reduced tear production.

Serious or Rare Side Effects: - Uveitis: inflammation of the uveal tract. - Macular edema: swelling of the central retina. - Vision loss: sudden decrease in visual acuity.

When prescribing Bimatoprost eye drops, clinicians should consider the following precautions to ensure safe use. - Contraindication: avoid use in patients with active ocular inflammation. - Caution: monitor patients with a history of uveitis or retinal disease. - Pregnancy: safety not established; use only if potential benefit justifies risk. - Breastfeeding: unknown excretion; weigh benefits against potential infant exposure. - Contact lens wearers: may experience lens discoloration; advise removal before instillation. - Store at room temperature: keep bottle in original packaging, protect from light and moisture.

Bimatoprost may interact with other ocular or systemic agents; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Concurrent use with other prostaglandin analog eye drops: additive IOP lowering may cause hypotony. - Combination with systemic carbonic anhydrase inhibitors: increased risk of ocular hypotension. - Use with ocular hyperemia‑inducing agents (e.g., topical vasodilators): may exacerbate redness.

Moderate Interactions (Monitor Closely): - Co‑administration with topical corticosteroids: may reduce steroid efficacy and increase intra‑ocular pressure fluctuations. - Use with contact lens solutions containing preservatives: may increase ocular irritation.